Understand the source comparison
Pe-22-28 Rapid-Acting Antidepressants: Mechanism Comparison
Comparing rapid-acting antidepressant mechanisms side-by-side clarifies why Pe-22-28 stands apart from other candidates. This table summarizes the key pharmacological, temporal, and mechanistic differences between Pe-22-28, ketamine, scopolamine, and tradition
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Comparing rapid-acting antidepressant mechanisms side-by-side clarifies why Pe-22-28 stands apart from other candidates. This table summarizes the key pharmacological, temporal, and mechanistic differences between Pe-22-28, ketamine, scopolamine, and traditional SSRIs.
- Pe-22-28
- TrkA receptor agonist. Activates NGF signaling, stimulates synaptic protein synthesis and dendritic branching
- 2–6 hours in preclinical models
- 7–10 days after single dose
- Human clinical trial data limited; optimal dosing and delivery route still under investigation
- Most mechanistically aligned with synaptic atrophy hypothesis; lacks dissociative or anticholinergic side effects seen in alternatives
- Ketamine
- NMDA receptor antagonist. Triggers glutamate surge and downstream BDNF release
- 2–4 hours (IV administration)
- 7–14 days; requires repeat infusions
- Dissociative side effects, abuse potential, requires medical supervision for administration
- Fastest onset with robust human data, but short durability and psychotomimetic effects limit scalability
- Scopolamine
- Muscarinic acetylcholine receptor antagonist. Unclear downstream mechanism
- 3–5 days
- 7–14 days
- Anticholinergic side effects (dry mouth, blurred vision, cognitive impairment) poorly tolerated
- Rapid onset but intolerable side effect profile limits real-world use
- SSRIs (e.g., fluoxetine, sertraline)
- Serotonin reuptake inhibition. Indirect BDNF upregulation over weeks
- 4–8 weeks
- Continuous with daily dosing; relapse common upon discontinuation
- 30–40% of patients show inadequate response; high discontinuation rates due to delayed onset
- Standard of care but mechanistically inadequate for treatment-resistant depression or acute suicidality